IL17A and systemic sclerosis: IL-17A mRNA expression was reduced in SSc-derived PBMCs treated with 1,25(OH)2D3 10-9M, 10-8M and 10-7M from 2.5-fold (untreated cells) to 2-fold (p<0.05), 1.8-fold (p<0.01), 1.51-fold (p<0.001) compared to control and to 0.82-fold (n.s.), 0.5-fold (p<0,001), 0.3-fold (p<0,0001) in PBMCs from healthy subjects, respectively.